Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 20;78(3):719-722.
doi: 10.1093/cid/ciad643.

Association of Cytomegalovirus (CMV) DNAemia With Long-Term Mortality in a Randomized Trial of Preemptive Therapy and Antiviral Prophylaxis for Prevention of CMV Disease in High-Risk Donor Seropositive, Recipient Seronegative Liver Transplant Recipients

Lakshin Kumar  1 , Sayan Dasgupta  2 , Cristina Murray-Krezan  3 , Nina Singh  4 , Robert M Rakita  1 , Cynthia E Fisher  1 , Ajit P Limaye  1
Affiliations

Association of Cytomegalovirus (CMV) DNAemia With Long-Term Mortality in a Randomized Trial of Preemptive Therapy and Antiviral Prophylaxis for Prevention of CMV Disease in High-Risk Donor Seropositive, Recipient Seronegative Liver Transplant Recipients

Lakshin Kumar et al. Clin Infect Dis. .

Abstract

In a post-hoc analysis of the association of CMV DNAemia with long-term mortality in a randomized trial of CMV preemptive therapy vs. antiviral prophylaxis in D+R- liver transplant recipients, post-intervention CMV DNAemia was associated with increased mortality after adjusting for study arm.

Keywords: antiviral therapy; cytomegalovirus; immunocompromised host; liver transplant; viral infections.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. A. P. L. is a consulting and/or site investigator for and has received institutional payments from Merck & Co, GlaxoSmithKline, Moderna, and Takeda Pharmaceuticals; has received institutional support via consulting fees from AiCures and Vera Therapeutics; reports consulting fees from Merck & Co, Moderna, AlloVir, and GlaxoSmithKline; and was reimbursed for participation on a data and safety monitoring board for Novartis, Syneos, and NobelPharma. C. E. F. is a consulting and/or site investigator holding grants or contracts unrelated to the study for Moderna and Amplyx Pharmaceuticals, Inc; has received support from National Institutes of Health (NIH); reports honoraria from NIH for serving as a VIDD study section ad hoc member; has received travel reimbursement from NIH; and was an unpaid participant of the United Network for Organ Sharing Disease Transmission Advisory Committee. C. M. K. has received institutional funding support unrelated to this article from the NIH, Patient-Centered Outcomes Research Institute (PCORI), and University of New Mexico; was reimbursed for travel expenses for participation on a clinical trials advisory panel for PCORI; and has received honoraria for leadership positions as chair for the PCORI Clinical Trials Advisory Panel and co-chair for the Membership Committee of the Society for Clinical Trials. S. D. has received institutional support from NIH (National Cancer Institute/National Institute of Allergy and Infectious Disease), University of Washington, Gilead Sciences, Inc, and Merck & Co and employee travel support from the Fred Hutchinson Cancer Center. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Figures

Graphical Abstract
Graphical Abstract
This graphical abstract is also available at Tidbit: https://tidbitapp.io/tidbits/association-of-cmv-dnaemia-with-long-term-mortality-in-a-randomized-trial-of-preemptive-therapy-pet-and-antiviral-prophylaxis-ap-for-prevention-of-cmv-disease-in-high-risk-donor-seropositive-recipient-se-2480b1a4-e573-43a6-973b-94ea264eed04
Figure 1.
Figure 1.
Comparisons of mortality in participants who completed the intervention period and late-onset CMV DNAemia in donor-seropositive, recipient-seronegative liver transplant recipients. A, Kaplan–Meier survival curve of participant who survived and completed the assigned intervention. B, Kaplan–Meier survival curve of participants who survived to 12 months post-transplant. C, Comparison of percent of participants who developed CMV DNAemia at 6 months and 12 months post-transplant. Analysis was limited to participants who survived to 12 months post-transplant. D, Violin plots of CMV DNAemia showing distribution of log10 (CMV viral load) at 6 and 12 months post-transplant in participants who survived to 12 months post-transplant. Abbreviations: CMV, cytomegalovirus; PET, preemptive therapy; tx, treatment.
See this image and copyright information in PMC

Comment in

References

    1. Singh N, Winston DJ, Razonable RR, et al. Effect of preemptive therapy vs antiviral prophylaxis on cytomegalovirus disease in seronegative liver transplant recipients with seropositive donors: a randomized clinical trial. JAMA 2020; 323:1378–87. - PMC - PubMed
    1. Zhang Z, Reinikainen J, Adeleke KA, Pieterse ME, Groothuis-Oudshoorn CGM. Time-varying covariates and coefficients in Cox regression models. Ann Transl Med 2018; 6:121. - PMC - PubMed
    1. Austin PC, Latouche A, Fine JP. A review of the use of time-varying covariates in the Fine-Gray subdistribution hazard competing risk regression model. Stat Med 2020; 39:103–13.. - PMC - PubMed
    1. Mumtaz K, Faisal N, Husain S, Morillo A, Renner EL, Shah PS. Universal prophylaxis or preemptive strategy for cytomegalovirus disease after liver transplantation: a systematic review and meta-analysis. Am J Transplant 2015; 15:472–81. - PubMed
    1. Yadav DK, Adhikari VP, Yadav RK, et al. Antiviral prophylaxis or preemptive therapy for cytomegalovirus after liver transplantation?: a systematic review and meta-analysis. Front Immunol 2022; 13:953210. - PMC - PubMed

Publication types

Substances